A Non-Randomized, Open-Label, Drug-Drug Interaction Study to Evaluate the Effects of Fluconazole on the Pharmacokinetics and Safety of EDP-938 in Healthy Subjects
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
24
Subjects will receive EDP-938 once daily on Days 1 and 14
Subjects will receive fluconazole once daily on Days 5 to 18
Pharmaceutical Research Associates, Inc.,
Salt Lake City, Utah, United States
Cmax of EDP-938 with and without coadministration with fluconazole
Time frame: Up to 19 days
AUC of EDP-938 with and without coadministration with fluconazole
Time frame: Up to 19 days
Safety measured by adverse events
Time frame: Up to 25 Days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.